This trial is testing whether a potential new therapy for Parkinson's disease, called tributyrin, is safe and effective.
2 Primary · 4 Secondary · Reporting Duration: after approximately 30 days of intervention
20 Total Participants · 1 Treatment Group
Primary Treatment: tributyrin · No Placebo Group · Phase 1
Participation is compensated
You will be compensated for participating in this trial.
Age 18+ · All Participants · 2 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: